Ikarian Capital, LLC Vaxcyte, Inc. Transaction History

Ikarian Capital, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $111,182 - $128,342	2,417 Added 1.73%	142,417 $7.26 Million
Q2 2023 Aug 14, 2023	SELL	$34.66 - $54.07 $2.95 Million - $4.6 Million	-85,000 Reduced 37.78%	140,000 $6.99 Million
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $906,750 - $1.18 Million	-25,000 Reduced 10.0%	225,000 $8.43 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $5.15 Million - $12 Million	250,000 New	250,000 $12 Million
Q2 2022 Aug 12, 2022	SELL	$17.68 - $26.58 $1.59 Million - $2.39 Million	-90,000 Reduced 28.48%	225,991 $4.92 Million
Q1 2022 May 13, 2022	BUY	$17.46 - $26.36 $364,564 - $550,396	20,880 Added 7.08%	315,991 $7.63 Million
Q3 2021 Nov 15, 2021	SELL	$20.26 - $26.97 $3.1 Million - $4.13 Million	-152,999 Reduced 34.14%	295,111 $7.49 Million
Q2 2021 Aug 16, 2021	SELL	$16.45 - $24.06 $871,850 - $1.28 Million	-53,000 Reduced 10.58%	448,110 $10.1 Million
Q1 2021 May 17, 2021	BUY	$18.66 - $29.16 $4.2 Million - $6.56 Million	225,000 Added 81.49%	501,110 $9.9 Million
Q4 2020 Feb 12, 2021	BUY	$26.57 - $51.74 $6.91 Million - $13.5 Million	260,000 Added 1613.9%	276,110 $7.34 Million
Q3 2020 Nov 16, 2020	SELL	$26.5 - $55.4 $3.28 Million - $6.85 Million	-123,703 Reduced 88.48%	16,110 $796,000
Q2 2020 Aug 14, 2020	BUY	$26.15 - $35.45 $3.66 Million - $4.96 Million	139,813 New	139,813 $4.42 Million

353

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.13B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.